Boston, December 19, 2025
Syremis Therapeutics has raised $165 million in Series A funding to advance their research in treating schizophrenia and other psychotic disorders. This significant investment underscores Boston’s role as a leading biotech hub, attracting private investment and fostering innovation. The company’s lead program, ST-905, is currently in Phase 1 development and aims to offer better treatment options for mental health conditions. As Boston’s biotech ecosystem thrives, the launch of Syremis exemplifies the region’s commitment to addressing critical health challenges.
Boston
Boston Biotech Soars: Syremis Secures $165M for Schizophrenia Research
A significant Series A funding round propels Syremis Therapeutics, signaling robust private investment and promising advancements in the fight against psychotic disorders, further solidifying Boston’s role as a hub for medical innovation.
Boston’s vibrant ecosystem continues to attract substantial private investment, fostering a landscape where entrepreneurial vision can thrive. The recent launch of Syremis Therapeutics exemplifies the spirit of innovation that defines Boston MA business. This new clinical-stage biopharmaceutical company, established on December 18, 2025, has successfully secured an impressive $165 million in Series A financing. Such significant capital infusions are crucial for supporting the groundbreaking work of Massachusetts entrepreneurs dedicated to addressing some of the most pressing health challenges of our time.
The commitment shown by investors in Syremis Therapeutics underscores a collective belief in the power of private enterprise and focused research to deliver meaningful solutions. This launch not only represents a major milestone for the company itself but also reinforces Boston’s reputation as a global leader in the biotechnology sector, a place where innovation is encouraged and where the ambition to tackle complex medical conditions is actively supported.
Syremis Therapeutics: Advancing Neuropsychiatric Care
Syremis Therapeutics has emerged with a focused mission: to develop novel medicines aimed at making a profound impact on the treatment of mental health conditions, particularly schizophrenia and other psychotic disorders. These conditions affect millions worldwide, presenting significant challenges in terms of efficacy and tolerability with existing treatments. The company’s pipeline is rooted in emerging scientific and clinically validated mechanisms of action.
The lead program for Syremis is ST-905, a dual M1/M4 muscarinic agonist currently in Phase 1 development. This compound is being explored for its potential in treating schizophrenia and other neuropsychiatric conditions. The company believes ST-905 possesses differentiated potency and favorable pharmaceutical properties, positioning it as a potential best-in-class therapy. Such targeted biotech innovation is vital for patients seeking improved therapeutic options.
A $165 Million Boost to Research and Development
The substantial $165 million Series A funding round, announced upon the company’s launch, provides Syremis Therapeutics with critical resources to advance its ambitious research and development agenda. This round was co-led by Dexcel Pharma and Third Rock Ventures, with additional participation from prominent investors including Bain Capital Life Sciences, GV (Google Ventures), QVT, and Pictet. This collective show of confidence from leading investment firms highlights the perceived potential of Syremis’s scientific approach and its leadership team.
The financing is specifically intended to support the advancement of Syremis’s pipeline through clinical proof of concept. This infusion of capital is a testament to the effectiveness of private markets in allocating resources to high-potential ventures. It enables companies like Syremis to pursue long-term research goals that might otherwise be hindered by more restrictive funding environments, ultimately contributing to economic growth through scientific progress.
Boston’s Enduring Role as a Biotech Hub
With a presence in both Tel Aviv and Boston, Syremis Therapeutics leverages the strengths of two dynamic centers for scientific and entrepreneurial activity. Boston, in particular, continues to be a magnet for life sciences companies due to its unparalleled academic institutions, a skilled workforce, and a supportive regulatory climate that encourages biotech innovation. The city’s dense network of hospitals, research labs, and venture capital firms creates a fertile ground for new companies to emerge and scale.
The presence of seasoned leaders in the founding team, including Elisabeth Kogan as Co-Founder and CEO, Elena Kagan as Co-Founder and Chief Development Officer, and Menashe Levy as Co-Founder and Chief Technology Officer, further strengthens Syremis’s position. Steve Paul, a co-founder and former CEO of Karuna Therapeutics, also serves on the Board of Directors. Their collective experience underscores the caliber of talent drawn to and nurtured within the Boston MA business environment. This concentration of expertise is a significant factor in attracting the substantial private investment seen in companies like Syremis.
Economic Momentum and Community Impact
The launch of Syremis Therapeutics, backed by substantial funding, carries significant implications for Boston’s economic growth. New biotech ventures typically generate high-skill jobs, from researchers and scientists to administrative and support staff, creating a ripple effect throughout the local economy. These jobs often lead to increased spending in other sectors, contributing to the overall prosperity of the region.
Moreover, the success of companies like Syremis can attract further investment into the local biotech cluster, creating a virtuous cycle of growth and innovation. This entrepreneurial drive, coupled with strategic private capital, is essential for maintaining Boston’s competitive edge and ensuring that the benefits of scientific advancement translate into tangible community advantages, including a stronger job market for Massachusetts entrepreneurs and residents alike.
The Promise of Private Enterprise in Health Innovation
The emergence of Syremis Therapeutics is a powerful example of how private enterprise and dedicated biotech innovation can drive progress in critical areas of public health. By focusing on challenging conditions like schizophrenia, Syremis aims to provide better treatment options, which can significantly improve the quality of life for many individuals and their families. This reflects a commitment to personal achievement within the scientific community, driven by the potential for meaningful impact.
Continued support for an environment that encourages entrepreneurial risk-taking and allows private investment to flow into promising research is paramount. Such an approach not only accelerates the development of new therapies but also strengthens the regional economy, demonstrating the profound interplay between scientific ingenuity and sound economic principles.
The launch of Syremis Therapeutics with its impressive Series A funding marks another significant chapter in Boston’s dynamic biotech story. This venture, focused on groundbreaking treatments for mental health, highlights the resilience and innovative spirit of Massachusetts entrepreneurs and the vital role of private investment in driving scientific progress and regional economic growth. We encourage our readers to stay engaged with the ongoing advancements within Boston’s thriving biotech sector, recognizing the local impact of global innovation.
Frequently Asked Questions
When did Syremis Therapeutics launch?
Syremis Therapeutics launched on December 18, 2025.
How much funding did Syremis Therapeutics raise in its Series A round?
Syremis Therapeutics raised $165 million in its Series A funding round.
What is the primary focus of Syremis Therapeutics?
Syremis Therapeutics focuses on developing novel medicines aimed at making a profound impact on the treatment of mental health conditions, particularly schizophrenia and other psychotic disorders.
Who co-led the Series A funding round for Syremis Therapeutics?
The Series A funding round for Syremis Therapeutics was co-led by Dexcel Pharma and Third Rock Ventures.
What is the lead program for Syremis Therapeutics?
The lead program for Syremis Therapeutics is ST-905, a dual M1/M4 muscarinic agonist in Phase 1 development for schizophrenia and other neuropsychiatric conditions.
Where is Syremis Therapeutics based?
Syremis Therapeutics is based in Tel Aviv and Boston.
Key Features of Syremis Therapeutics Launch
| Company Name | Syremis Therapeutics |
| Launch Date | December 18, 2025 |
| Funding Round | Series A |
| Amount Raised | $165 million |
| Primary Focus | Developing medicines for schizophrenia and other psychotic disorders |
| Co-Lead Investors (Series A) | Dexcel Pharma and Third Rock Ventures |
| Lead Program | ST-905 (dual M1/M4 muscarinic agonist) |
| Program Stage | Phase 1 development |
| Headquarters Locations | Tel Aviv and Boston |
Deeper Dive: News & Info About This Topic
HERE Resources
Eastern Edge: A New Chapter for Kendall Square
Senate Deadlock Threatens Small Business Innovation Funding
Lila Sciences Secures Major Lease at Alewife Park
Quincy to Transform Presidents Place into Life Science Hub
Revvity Inc. to Cut Over 100 Jobs in Massachusetts
Massachusetts Faces Rising Unemployment and Job Cuts
Governor Maura Healey Establishes Advisory Council on Competitiveness
Revvity Inc. to Cut Over 100 Jobs in Massachusetts
Major Layoffs Hit Biopharma Sector as Companies Restructure
Boston’s Biotech Sector Faces Unprecedented Challenges
Author: STAFF HERE BOSTON WRITER
The BOSTON STAFF WRITER represents the experienced team at HEREBoston.com, your go-to source for actionable local news and information in Boston, Suffolk County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as Boston Marathon, Head of the Charles Regatta, and Boston Harborfest. Our coverage extends to key organizations like the Greater Boston Chamber of Commerce and Associated Industries of Massachusetts, plus leading businesses in finance, biotech, and insurance that power the local economy such as Fidelity Investments, Biogen, and Liberty Mutual Insurance. As part of the broader HERE network, we provide comprehensive, credible insights into Massachusetts's dynamic landscape.
